logo
Japanese quail: The bird with weird sperm foam, a post-sex strut and a spot in space history

Japanese quail: The bird with weird sperm foam, a post-sex strut and a spot in space history

Yahoo2 days ago
When you buy through links on our articles, Future and its syndication partners may earn a commission.
QUICK FACTS
Name: Japanese quail (Coturnix japonica)
Where it lives: Steppes and meadows in Asia, notably China, India, Japan, Korea and Russia. It's also found in Africa and parts of Europe. Some populations are migratory.
What it eats: Seeds of grasses, as well as small insects and other invertebrates.
Japanese quail are small relatives of chickens and turkeys with one very unusual trait — males produce a unique seminal foam that resembles meringue.
The foam is unusual among birds but turkeys produce a similar substance.
Japanese quails were bred in captivity as early as the 11th century and were initially kept for their melodic songs. But they were later exploited for their meat and eggs.
The tiny birds, which weigh between 3.5 and 10.5 ounces (100 and 300 grams), reach sexual maturity by around 6 weeks and females are prolific egg layers, producing between 250 and 300 per year. Because of this, they're also very popular for scientific research. And in 1990, they became the first birds to be incubated and hatched in space.
Scientists first noticed Japanese quails had unusual foamy semen in the 1950s, and it has been the subject of research ever since. Their unique seminal foam is produced during mating by the proctodeal gland in the cloaca — the cavity containing both the excretory and reproductive organs — and is thought to enhance the chances of successful fertilization of a female's egg.
The foam joins seminal fluid and the sperm itself upon ejaculation. Its bubbly consistency is created by contractions of the muscles in the cloaca that amplify the effects of gases released by microorganisms in the cavity.
RELATED STORIES
—Southern cassowary: The giant prehistoric bird with dinosaur feet—Great eared nightjar: The 'baby dragon' bird that lays its eggs on the floor—Dracula parrot: The goth bird whose piercing screams echo through New Guinea forests
The foam is believed to help sperm cells mature after they enter the female reproductive tract, where they are stored for 8 to 11 days before fertilization occurs. It may also enhance the motility of the sperm and protect it from bacteria.
After a successful insemination, males do a little strut.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Scientists are holding a ‘science fair' in the lobby of a Congressional building to show what the US stands to lose with cuts
Scientists are holding a ‘science fair' in the lobby of a Congressional building to show what the US stands to lose with cuts

Fast Company

time2 hours ago

  • Fast Company

Scientists are holding a ‘science fair' in the lobby of a Congressional building to show what the US stands to lose with cuts

All's fair on Capitol Hill. In response to the Trump administration's wide-ranging science cuts and grant cancellations, researchers and scientists staged a 'science fair' in the lobby of a Congressional building in Washington D.C. to bring awareness to what potential knowledge the United States could miss out on as a result. The fair is being held just days after Trump signed the 'Big, Beautiful Bill' into law, which codifies many spending cuts and funding cancellations for scientific endeavors of all types—from climate research to medical trials. Billions of dollars that were destined for researchers and scientists in the National Institutes of Health, National Science Foundation, and other organizations. In effect, the U.S. is ceding its place as a leader in research and development—a role it has held for decades, and which has led to the development of cures for diseases and disorders, advanced military technology, and, of course, put a man on the moon. The funding cuts and cancellations are widespread, and it's difficult to lasso them all. But even with what's been cancelled or clawed back so far, Trump is looking to reduce spending on science further. In the budget request he released in May, billions more would be cut from NIH, NSF, the Department of Education, and completely eliminate funding for the Institute of Museum and Library Sciences, and more. In response, Sudip Parikh, CEO of the American Association for the Advancement of Science (AAAS), released a statement saying just how dangerous the cuts could be. 'If enacted, the FY26 budget request would end America's global scientific leadership. The cuts to science would imperil our nation's future health, security and prosperity. This budget proposal stands in stark contrast to the President's call for a renewed commitment to American scientific leadership,' he wrote. 'Congress has demonstrated a bipartisan commitment to investment in research and must do so again to answer the President's call. That's all to say that despite the demonstrations by scientists, and the potential long-term economic effects of cuts, the Trump administration may still not be done. Just within the past couple of days, Trump cut off researchers in the U.K. from utilizing data collected by U.S. satellites to study pollution and climate change, according to reporting from the U.K.-based The i Paper. Per that report, Rachel Cauley, OMB communications director at the White House, responded to worried scientists by saying that 'President Trump ran on defunding woke, weaponized, and wasteful government and his budget proudly does that by cutting funding for the Green New Scam, projects like 'gender-responsive agricultural adaptation' in Guatemala and Mexico, and 'Equity Climate and Health' workshops for 'transgender women, and those who identify as non-binary.' Under Trump's leadership, the US is funding real science again.'

JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines
JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines

Associated Press

time3 hours ago

  • Associated Press

JCR Pharmaceuticals Enters License Agreement with Alexion for Proprietary JUST-AAV Capsids to be Used in the Development of Genomic Medicines

HYOGO, Japan--(BUSINESS WIRE)--Jul 8, 2025-- JCR Pharmaceuticals Co., Ltd. (TSE 4552; 'JCR') today announced that it has entered into a license agreement with Alexion, AstraZeneca Rare Disease ('Alexion'), for JCR's new, proprietary JUST-AAV capsids to develop genomic medicines. JUST-AAV encompasses a range of vector types optimized for various target tissues—including liver-sparing, muscle-targeting, and brain-targeting variants—to expand the potential of AAV-based gene therapy. Under the terms of the agreement, Alexion may use the licensed capsids, which are part of the JUST-AAV platform, in up to five of Alexion's genomic medicines programs. JCR will receive an upfront payment from Alexion. JCR is eligible to receive milestone payments of up to USD 225 million related to research and development, and up to USD 600 million related to sales, for a total of up to USD 825 million (approximately JPY 120 billion converted at the exchange rate of JPY 145 to USD), which reflects the aggregate milestones if all five targets are exercised. In addition, JCR is entitled to receive tiered royalties based on net sales. This agreement marks the third partnership between JCR and Alexion, following research collaborations involving J-Brain Cargo ® technology— the first announced in March 2023 for neurodegenerative disease and the second announced in December 2023 for the discovery of oligonucleotide therapeutics. 'I am very pleased to announce the signing of this license agreement for our proprietary AAV capsid platform, JUST-AAV,' said Shin Ashida, Chairman, President and CEO of JCR Pharmaceuticals. 'I believe JUST-AAV has the potential to make a real difference in the development of gene therapies for rare diseases, and I look forward to its application across a broader range of conditions. JCR values its partnership with Alexion, and we are pleased to build on the collaboration we have developed over the years.' The impact of this agreement on JCR's consolidated financial results for the fiscal year ending March 31, 2026, has already been factored into the current earnings forecast. View source version on CONTACT: Investors & Media: JCR Pharmaceuticals Co., Ltd. Corporate Communications [email protected] KEYWORD: JAPAN ASIA PACIFIC INDUSTRY KEYWORD: SCIENCE OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL GENERAL HEALTH HEALTH HEALTH TECHNOLOGY SOURCE: JCR Pharmaceuticals Co., Ltd. Copyright Business Wire 2025. PUB: 07/08/2025 01:58 PM/DISC: 07/08/2025 01:57 PM

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store